$0.36
0.50%
Nasdaq, Oct 01, 04:00 pm EDT. Closed.
ISIN
US8342233074
Symbol
SNGX

Soligenix, Inc. Stock price

$0.36
-0.01 3.24% 1M
-0.79 68.37% 6M
-0.98 72.85% YTD
-0.88 70.66% 1Y
-8.87 96.06% 3Y
-251.38 99.86% 5Y
-190.22 99.81% 10Y
-83.55 99.57% 20Y
Nasdaq, Closing price Thu, Oct 01 2026
+0.00 0.50%
ISIN
US8342233074
Symbol
SNGX
Industry

Is Soligenix, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$7.9m
Enterprise Value
$-1.9m
Net debt
positive
Cash
$9.8m
Shares outstanding
21.6m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.2
P/B
1.2
Financial Health
Equity Ratio
57.3%
Return on Equity
-209.4%
ROCE
-161.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-11.0m
EBIT
$-11.0m
Net Income
$-10.2m
Free Cash Flow
$-9.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
5.2%
EBIT
5.3%
Net Income
3.8%
Free Cash Flow
0.0%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-0.6
FCF per Share
$-0.5
Short interest
0.9%
Employees
15
Rev per Employee
$0.0

Soligenix, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Soligenix, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Soligenix, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Soligenix, Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.42 4.42
7% 7%
-
- Research and Development Expense 6.62 6.62
12% 12%
-
-11 -11
5% 5%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -11 -11
5% 5%
-
Net Profit -10 -10
4% 4%
-

In millions USD.

Don't miss a Thing! We will send you all news about Soligenix, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Soligenix, Inc. Stock News

Neutral
PRNewsWire
●
about 2 months ago
PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent updates and financial results for the quarter ended June 30, 2026.
Neutral
PRNewsWire
●
4 months ago
Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development PRINCETON, N.J., June 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted to...
Neutral
PRNewsWire
●
4 months ago
Thermostability, immunogenicity and efficacy data against related virusesmay provide rapid starting point for vaccine development PRINCETON, N.J., May 26, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today...
More Soligenix, Inc. News

Company Profile

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Head office United States
CEO Dr. Schaber
Employees 15
Founded 1987
Website www.soligenix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today